This is not the most recent version of the article. View current version (15 FEB 2012)

Intervention Protocol

Alemtuzumab for chronic lymphocytic leukaemia

  1. Thomas Elter1,*,
  2. Olaf Weingart2,
  3. Kathrin Bauer2,
  4. Corinne Brillant2,
  5. Christine Herbst2,
  6. Ina Monsef2,
  7. Nicole Skoetz2,
  8. Andreas Engert2

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 30 MAR 2009

DOI: 10.1002/14651858.CD008078

How to Cite

Elter T, Weingart O, Bauer K, Brillant C, Herbst C, Monsef I, Skoetz N, Engert A. Alemtuzumab for chronic lymphocytic leukaemia (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD008078. DOI: 10.1002/14651858.CD008078.

Author Information

  1. 1

    University Hospital of Cologne, Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, Cologne, Germany

  2. 2

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

*Thomas Elter, Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. thomas.elter@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 7 OCT 2009

SEARCH

This is not the most recent version of the article.View current version (15 Feb 2012)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via Athens http://onlinelibrary.wiley.com/athens or other institutional login options http://onlinelibrary.wiley.com/login-options .
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >